Metraipolis › archive › dc_f3567dd346cd

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens — Europe PMC PMID:42120493

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42120493
DOI: 10.1038/s44321-[numero omesso]-7
License (as archived): solo-consultazione
Archived: 2026-11-02T09:28:38.822Z
SHA-256 of the archived text: 2e2dd92d18954e27dc24793b1ec8ad9d2ba4af914e8c2375a9bc2e92a1ce9401
Stable URL of this page: https://metraipolis.com/documento/dc_f3567dd346cd

How to cite

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens — Europe PMC PMID:42120493 — Europe PMC (en), https://europepmc.org/article/MED/42120493 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f3567dd346cd (Metraipolis archive dc_f3567dd346cd, sha256 2e2dd92d18954e27dc24793b1ec8ad9d2ba4af914e8c2375a9bc2e92a1ce9401)

BibTeX

@misc{dcf3567dd346cd,
  title = {TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens — Europe PMC PMID:42120493},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42120493},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f3567dd346cd; sha256 2e2dd92d18954e27dc24793b1ec8ad9d2ba4af914e8c2375a9bc2e92a1ce9401},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42120493. Agents can read the archived copy with the MCP tool read_document.